{"title":"生物治疗难治性 RA","authors":"Jessica McHugh","doi":"10.1038/s41584-024-01132-6","DOIUrl":null,"url":null,"abstract":"The bispecific T cell engager (BiTE) blinatumomab showed promising clinical efficacy in a pilot study of six patients with multidrug-resistant rheumatoid arthritis.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"20 7","pages":"395-395"},"PeriodicalIF":29.4000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"BiTEing refractory RA\",\"authors\":\"Jessica McHugh\",\"doi\":\"10.1038/s41584-024-01132-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The bispecific T cell engager (BiTE) blinatumomab showed promising clinical efficacy in a pilot study of six patients with multidrug-resistant rheumatoid arthritis.\",\"PeriodicalId\":18810,\"journal\":{\"name\":\"Nature Reviews Rheumatology\",\"volume\":\"20 7\",\"pages\":\"395-395\"},\"PeriodicalIF\":29.4000,\"publicationDate\":\"2024-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41584-024-01132-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41584-024-01132-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
The bispecific T cell engager (BiTE) blinatumomab showed promising clinical efficacy in a pilot study of six patients with multidrug-resistant rheumatoid arthritis.
期刊介绍:
Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.